Brand Name
Elevidys
Generic Name
Delandistrogene Moxeparvovec-Rokl
View Brand Information FDA approval date: June 22, 2023
Form: Kit
What is Elevidys (Delandistrogene Moxeparvovec-Rokl)?
ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy in individuals at least 4 years of age: For patients who are ambulatory and have a confirmed mutation in the DMD gene [see Clinical Pharmacology ( 1.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment